Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed adults with HIV-1
2014-005550-18Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Delstrigo in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion maintaining HIV-1 RNA <50 copies/mL. Started May 2015; status: completed.
02
Drugs
Delstrigo
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-005550-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005550-18.